How Does CGRP Work? Mechanism of Action, Per the Research

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide produced by alternative splicing of the calcitonin gene and released primarily from sensory neurons. A 2023 review in Physiological Reviews described CGRP physiology and pharmacology in detail, covering its receptor biology, its distribution in trigeminal and spinal sensory neurons, and the therapeutic programmes built around it (PMID 36454715). This page summarises what the published literature reports about how CGRP works, labels in-vitro and animal findings as such, and separates well-characterised pharmacology from mechanisms still described as proposed.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health or treatment decision. No dosing, protocol or administration information appears here.

What CGRP Is and Where It Comes From

The Physiological Reviews article described CGRP as existing in two forms, α-CGRP and β-CGRP, with α-CGRP generated by tissue-specific splicing of the calcitonin/CGRP gene and expressed heavily in sensory neurons, while β-CGRP was described as more prominent in enteric neurons (PMID 36454715). The same review reported that CGRP-containing nerve fibres densely innervate blood vessels, the meninges, skin, bone and the gastrointestinal tract, which is the anatomical basis for the wide range of effects attributed to the peptide (PMID 36454715).

A 2018 review in Nature Reviews Neurology traced CGRP from its discovery through to clinical translation, describing how the peptide was identified in trigeminal sensory neurons and how that localisation motivated the drug programmes that followed (PMID 29691490).

The Receptor: CLR + RAMP1

The defining feature of CGRP pharmacology is that its canonical receptor is not a single protein. The Physiological Reviews survey described the CGRP receptor as a heterodimer of the calcitonin receptor-like receptor (CLR), a class B G protein-coupled receptor, together with receptor activity-modifying protein 1 (RAMP1), with receptor component protein (RCP) acting as an intracellular coupling partner (PMID 36454715). The same review reported that swapping RAMP1 for RAMP2 or RAMP3 changes the pharmacology of CLR toward adrenomedullin, and that CGRP can also act at the AMY₁ receptor formed by the calcitonin receptor plus RAMP1 — a source of overlap and cross-reactivity in the calcitonin peptide family (PMID 36454715).

This RAMP dependence explains why so much of the experimental literature manipulates RAMP1 rather than CLR. A 2024 study in Science Translational Medicine used CGRP/RAMP1 signalling between nociceptors and macrophages in mouse models of endometriosis, reporting that this axis contributed to pain behaviour and lesion growth in those mice (PMID 39504351). A 2024 PNAS paper similarly described a neuroimmune CGRP–RAMP1 axis tuning cutaneous adaptive immunity to the skin microbiota (PMID 38451947). Both were animal and cellular studies, not human trials.

Signalling Downstream of the Receptor

The Physiological Reviews account described the CGRP receptor as coupling principally to G_s, activating adenylate cyclase, raising intracellular cAMP and activating protein kinase A, with downstream consequences including opening of ATP-sensitive potassium channels in vascular smooth muscle and phosphorylation of ion channels and transcription factors such as CREB (PMID 36454715). The review also noted that signalling is not exclusively cAMP-dependent and that receptor internalisation and location-biased signalling have been reported in cell systems (PMID 36454715).

Vasodilation and Sensory Signalling

Vasodilation is the oldest and most consistently reported action of CGRP. The Physiological Reviews article described CGRP as among the most potent vasodilators characterised, acting both directly on vascular smooth muscle through cAMP and indirectly via endothelial nitric oxide, and discussed the cardiovascular implications of blocking that pathway pharmacologically (PMID 36454715).

In the trigeminovascular system, the 2018 Nature Reviews Neurology review described CGRP release from trigeminal afferents, elevated CGRP associated with migraine attacks, and the translation of that observation into antibodies and small-molecule receptor antagonists that target the peptide or its receptor (PMID 29691490). The authors framed this as one of the clearer examples of a neuropeptide mechanism moving from bench observation to approved pharmacology (PMID 29691490).

Sensitisation — the lowering of firing thresholds in pain pathways — is a separate mechanistic strand. A 2023 study in Brain reported that peripheral CCL2–CCR2 signalling contributed to chronic headache-related sensitisation in a rodent model, situating CGRP within a broader network of peripheral mediators rather than as a solitary driver (PMID 37284790).

CGRP Is Not Alone: PACAP and Parallel Pathways

A 2023 review in The Journal of Headache and Pain compared CGRP with pituitary adenylate cyclase-activating polypeptide (PACAP), describing shared and independent roles for the two neuropeptides in migraine pathophysiology and noting that both converge on cAMP-dependent signalling while acting at distinct receptors (PMID 37009867). A 2025 Cephalalgia review revisited the comparison from mouse models through to clinical translation, reporting that the two peptides appear to engage partly separate pathways rather than one being a simple substitute for the other (PMID 40931761). These comparisons matter mechanistically: they argue against a model in which CGRP accounts for the whole of a given physiological response.

Neuroimmune Mechanisms: Mostly Animal and Cell Work

A large share of recent CGRP mechanism research sits at the interface of nerves and immune cells, and nearly all of it is preclinical.

• A 2024 Nature study reported that neuropeptide signalling orchestrated T cell differentiation, placing neuropeptides including CGRP upstream of adaptive immune programming in experimental systems (PMID 39415015).
• A 2023 Nature paper reported that bacteria hijacked a meningeal neuroimmune axis to facilitate brain invasion, implicating nociceptor-derived CGRP signalling in the suppression of protective immune responses in mice (PMID 36859544).
• The 2024 PNAS study described the CGRP–RAMP1 axis tuning cutaneous adaptive immunity in response to the skin microbiota (PMID 38451947).
• The 2024 Science Translational Medicine study reported that nociceptor-to-macrophage CGRP/RAMP1 communication drove endometriosis-associated pain and lesion growth in mice (PMID 39504351).
• A 2025 paper in Clinical Science reported that CGRP alleviated lipopolysaccharide-induced ARDS inflammation via the HIF-1α signalling pathway in an experimental model (PMID 40110637).

Taken together, these reports describe CGRP as an immunomodulatory signal whose direction of effect appears context-dependent — dampening some inflammatory responses, as in the ARDS model (PMID 40110637), while contributing to pathology in others, as in the endometriosis model (PMID 39504351). Researchers have not resolved how these context differences translate to human physiology.

Bone, Tendon and Repair Signalling

Sensory nerves innervate bone and tendon, and several groups have examined whether CGRP signalling participates in repair. A 2024 study in Science Advances reported that activation of CGRP receptor-mediated signalling promoted tendon-bone healing in an experimental model (PMID 38457499). A 2024 paper in Cell Death and Differentiation reported that inhibiting inflammatory osteoclasts accelerated callus remodelling in osteoporotic fractures by enhancing CGRP⁺TrkA⁺ signalling (PMID 39223264). Both were preclinical studies; neither established a clinical effect in people.

Established Mechanism vs Proposed Mechanism

Well characterised in the published pharmacology

• CGRP binds a CLR–RAMP1 receptor complex and signals largely through G_s, cAMP and PKA, as described in the Physiological Reviews survey (PMID 36454715).
• CGRP is a potent vasodilator in multiple vascular beds (PMID 36454715).
• CGRP is expressed in trigeminal sensory neurons and has been targeted pharmacologically on that basis (PMID 29691490).

Described as proposed, model-dependent or preclinical

• Immune-cell modulation via RAMP1, including T cell differentiation (PMID 39415015) and meningeal host defence (PMID 36859544).
• Tissue-repair roles in tendon-bone healing (PMID 38457499) and fracture callus remodelling (PMID 39223264).
• Anti-inflammatory signalling through HIF-1α in lung injury models (PMID 40110637).
• The relative weighting of CGRP versus PACAP in headache pathways, still under active comparison (PMID 37009867, PMID 40931761).

What the Mechanism Literature Does Not Settle

Mechanistic plausibility is not the same as demonstrated clinical effect. The 2018 review noted that translation from receptor biology to clinical pharmacology took decades and involved failed as well as successful compounds (PMID 29691490). The 2023 physiology review emphasised that CGRP acts across many organ systems, so interventions aimed at one pathway intersect with others, including cardiovascular and gastrointestinal functions (PMID 36454715). Readers comparing animal results with human physiology should note species differences in RAMP1 pharmacology, which the same review discussed (PMID 36454715).

For an overview of CGRP biology, research contexts and regulatory status, see the related hub page at /learn/cgrp/. Again, this page is educational only and is not medical advice; decisions about any therapy belong with a licensed physician.

References

• CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond (Physiological Reviews, 2023)
• CGRP as the target of new migraine therapies — successful translation from bench to clinic (Nature Reviews Neurology, 2018)
• Bacteria hijack a meningeal neuroimmune axis to facilitate brain invasion (Nature, 2023)
• Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization (Brain, 2023)
• Neuropeptide signalling orchestrates T cell differentiation (Nature, 2024)
• Nociceptor-to-macrophage communication through CGRP/RAMP1 signaling drives endometriosis-associated pain and lesion growth in mice (Science Translational Medicine, 2024)
• Activation of CGRP receptor-mediated signaling promotes tendon-bone healing (Science Advances, 2024)
• Shared and independent roles of CGRP and PACAP in migraine pathophysiology (The Journal of Headache and Pain, 2023)
• The neuroimmune CGRP-RAMP1 axis tunes cutaneous adaptive immunity to the microbiota (PNAS, 2024)
• PACAP versus CGRP in migraine: From mouse models to clinical translation (Cephalalgia, 2025)
• CGRP alleviates lipopolysaccharide-induced ARDS inflammation via the HIF-1α signaling pathway (Clinical Science, 2025)
• Inhibition of inflammatory osteoclasts accelerates callus remodeling in osteoporotic fractures by enhancing CGRP(+)TrkA(+) signaling (Cell Death and Differentiation, 2024)